Treatment of idiopathic membranous nephropathy

J Am Soc Nephrol. 2012 Oct;23(10):1617-30. doi: 10.1681/ASN.2012010058. Epub 2012 Aug 2.


Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Adrenocorticotropic Hormone / therapeutic use
  • Alkylating Agents / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Calcineurin Inhibitors
  • Clinical Trials as Topic
  • Glomerulonephritis, Membranous / etiology
  • Glomerulonephritis, Membranous / immunology
  • Glomerulonephritis, Membranous / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Receptors, Phospholipase A2 / immunology
  • Rituximab


  • Alkylating Agents
  • Antibodies, Monoclonal, Murine-Derived
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Receptors, Phospholipase A2
  • Rituximab
  • Adrenocorticotropic Hormone
  • Mycophenolic Acid